CN116699003B - 昼夜节律体液标志物组合及其uplc-ms/ms检测方法 - Google Patents
昼夜节律体液标志物组合及其uplc-ms/ms检测方法 Download PDFInfo
- Publication number
- CN116699003B CN116699003B CN202310199328.XA CN202310199328A CN116699003B CN 116699003 B CN116699003 B CN 116699003B CN 202310199328 A CN202310199328 A CN 202310199328A CN 116699003 B CN116699003 B CN 116699003B
- Authority
- CN
- China
- Prior art keywords
- melatonin
- urine
- hydroxy
- cortisol
- testosterone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000027288 circadian rhythm Effects 0.000 title claims abstract description 26
- 239000003550 marker Substances 0.000 title claims abstract description 16
- 238000010811 Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry Methods 0.000 title claims abstract description 14
- 238000001514 detection method Methods 0.000 title abstract description 15
- 210000001124 body fluid Anatomy 0.000 title abstract description 8
- 239000010839 body fluid Substances 0.000 title abstract description 8
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims abstract description 58
- 210000002700 urine Anatomy 0.000 claims abstract description 55
- 229960003987 melatonin Drugs 0.000 claims abstract description 48
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims abstract description 47
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims abstract description 43
- 229960000890 hydrocortisone Drugs 0.000 claims abstract description 29
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 49
- CKAXPTWYSHDIBN-UHFFFAOYSA-N formyl-5-hydroxykynurenamine Chemical compound NCCC(=O)C1=CC(O)=CC=C1NC=O CKAXPTWYSHDIBN-UHFFFAOYSA-N 0.000 claims description 28
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims description 24
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims description 24
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims description 24
- 229960004544 cortisone Drugs 0.000 claims description 24
- 201000010063 epididymitis Diseases 0.000 claims description 23
- 229960003604 testosterone Drugs 0.000 claims description 23
- 210000000918 epididymis Anatomy 0.000 claims description 22
- QGXBDMJGAMFCBF-HLUDHZFRSA-N 5α-Androsterone Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 QGXBDMJGAMFCBF-HLUDHZFRSA-N 0.000 claims description 20
- QGXBDMJGAMFCBF-UHFFFAOYSA-N Etiocholanolone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC21 QGXBDMJGAMFCBF-UHFFFAOYSA-N 0.000 claims description 20
- 229940061641 androsterone Drugs 0.000 claims description 20
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 claims description 18
- 239000012491 analyte Substances 0.000 claims description 18
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 claims description 18
- 230000002060 circadian Effects 0.000 claims description 15
- 230000014759 maintenance of location Effects 0.000 claims description 15
- 238000000605 extraction Methods 0.000 claims description 14
- 239000000243 solution Substances 0.000 claims description 14
- QQEILXDLZRLTME-UHFFFAOYSA-N 6-sulfatoxymelatonin Chemical compound C1=C(OS(O)(=O)=O)C(OC)=CC2=C1NC=C2CCNC(C)=O QQEILXDLZRLTME-UHFFFAOYSA-N 0.000 claims description 13
- 150000002500 ions Chemical class 0.000 claims description 13
- 150000002576 ketones Chemical class 0.000 claims description 12
- 235000019253 formic acid Nutrition 0.000 claims description 10
- 238000002552 multiple reaction monitoring Methods 0.000 claims description 10
- 238000004458 analytical method Methods 0.000 claims description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 8
- DRLFMBDRBRZALE-NZLXMSDQSA-N n-[1,1,2,2-tetradeuterio-2-(5-methoxy-1h-indol-3-yl)ethyl]acetamide Chemical compound C1=C(OC)C=C2C(C([2H])([2H])C([2H])(NC(C)=O)[2H])=CNC2=C1 DRLFMBDRBRZALE-NZLXMSDQSA-N 0.000 claims description 8
- 239000012071 phase Substances 0.000 claims description 8
- 239000011550 stock solution Substances 0.000 claims description 8
- 238000004885 tandem mass spectrometry Methods 0.000 claims description 8
- QGXBDMJGAMFCBF-NGIKVBDRSA-N (3R,5S,8R,9S,10S,13S,14S)-2,2,4,4-tetradeuterio-3-hydroxy-10,13-dimethyl-1,3,5,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one Chemical compound [2H]C1([2H])C[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC[C@H]2C([2H])([2H])[C@@H]1O QGXBDMJGAMFCBF-NGIKVBDRSA-N 0.000 claims description 7
- OMFXVFTZEKFJBZ-VWODBOJYSA-N (8s,9s,10r,11s,13s,14s,17s)-2,2,4,6,6,17-hexadeuterio-17-(2,2-dideuterio-2-hydroxyacetyl)-11-hydroxy-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C([C@]1(C)[C@@]([2H])(C(=O)C([2H])([2H])O)CC[C@H]1[C@@H]1CC2([2H])[2H])[C@H](O)[C@@H]1[C@]1(C)C2=C([2H])C(=O)C([2H])([2H])C1 OMFXVFTZEKFJBZ-VWODBOJYSA-N 0.000 claims description 7
- OMYMRCXOJJZYKE-UHFFFAOYSA-N 6-hydroxymelatonin Chemical group C1=C(O)C(OC)=CC2=C1NC=C2CCNC(C)=O OMYMRCXOJJZYKE-UHFFFAOYSA-N 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 238000004445 quantitative analysis Methods 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 238000012544 monitoring process Methods 0.000 claims description 4
- 238000004704 ultra performance liquid chromatography Methods 0.000 claims description 4
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 239000007790 solid phase Substances 0.000 claims 1
- 239000002207 metabolite Substances 0.000 abstract description 18
- 238000011144 upstream manufacturing Methods 0.000 abstract description 4
- 230000002159 abnormal effect Effects 0.000 abstract description 2
- 229940088597 hormone Drugs 0.000 description 28
- 239000005556 hormone Substances 0.000 description 28
- 239000000523 sample Substances 0.000 description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 230000000694 effects Effects 0.000 description 10
- 239000011159 matrix material Substances 0.000 description 10
- 239000003270 steroid hormone Substances 0.000 description 9
- 230000002596 correlated effect Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 7
- 238000003908 quality control method Methods 0.000 description 7
- 239000003643 water by type Substances 0.000 description 7
- 238000011084 recovery Methods 0.000 description 6
- 230000033764 rhythmic process Effects 0.000 description 6
- 239000000090 biomarker Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- -1 cortisol-D4 Chemical compound 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000002452 interceptive effect Effects 0.000 description 4
- 238000012417 linear regression Methods 0.000 description 4
- 239000013062 quality control Sample Substances 0.000 description 4
- 210000003296 saliva Anatomy 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- SVWLIIFHXFGESG-UHFFFAOYSA-N formic acid;methanol Chemical compound OC.OC=O SVWLIIFHXFGESG-UHFFFAOYSA-N 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000006920 protein precipitation Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 208000019116 sleep disease Diseases 0.000 description 3
- 239000012086 standard solution Substances 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000001020 rhythmical effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 239000012901 Milli-Q water Substances 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 241001417494 Sciaenidae Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 208000025307 bipolar depression Diseases 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000003066 decision tree Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 231100000640 hair analysis Toxicity 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 210000004560 pineal gland Anatomy 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000012672 seasonal affective disease Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 1
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
- G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
分析物 | 范围(ng/mL) | 回归方程 | 相关性(r2) | LLOQ(ng/mL) |
褪黑素 | 0.0002~1 | Y=32.48X-0.0028 | 0.9957 | 0.0002 |
6-羟基褪黑素 | 0.0025~2.5 | Y=2.26X-0.0002 | 0.9985 | 0.0025 |
6-羟基硫酸褪黑素 | 0.02~20 | Y=2.58X+0.0026 | 0.9995 | 0.02 |
皮质醇 | 0.02~100 | Y=1.84X-0.0016 | 0.9993 | 0.02 |
皮质酮 | 0.05~50 | Y=0.24X+0.0019 | 0.9914 | 0.05 |
可的松 | 0.2~200 | Y=3.01X+0.0998 | 0.9939 | 0.2 |
睾酮 | 0.001~5 | Y=1.31X+0.0002 | 0.9994 | 0.001 |
表睾酮 | 0.001~5 | Y=1.45X+0.0070 | 0.9991 | 0.001 |
雄酮 | 0.02~10 | Y=0.07X+0.0007 | 0.9990 | 0.02 |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310199328.XA CN116699003B (zh) | 2023-03-03 | 2023-03-03 | 昼夜节律体液标志物组合及其uplc-ms/ms检测方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310199328.XA CN116699003B (zh) | 2023-03-03 | 2023-03-03 | 昼夜节律体液标志物组合及其uplc-ms/ms检测方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116699003A CN116699003A (zh) | 2023-09-05 |
CN116699003B true CN116699003B (zh) | 2023-12-26 |
Family
ID=87842192
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310199328.XA Active CN116699003B (zh) | 2023-03-03 | 2023-03-03 | 昼夜节律体液标志物组合及其uplc-ms/ms检测方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116699003B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102812124A (zh) * | 2009-08-26 | 2012-12-05 | 器官平衡有限责任公司 | 用于产生脂质的经遗传改造的生物 |
CN103336065A (zh) * | 2013-01-15 | 2013-10-02 | 东南大学 | 一种同时提取和检测生物介质中多种激素及其代谢物的方法 |
CN112964809A (zh) * | 2019-12-13 | 2021-06-15 | 中国科学院大连化学物理研究所 | 一种检测生物体液多种类固醇激素试剂盒及其使用方法 |
CN114813989A (zh) * | 2022-02-25 | 2022-07-29 | 东南大学 | 毛发中褪黑素、n-乙酰血清素、6-羟基褪黑素、皮质醇和可的松同时提取和检测方法 |
-
2023
- 2023-03-03 CN CN202310199328.XA patent/CN116699003B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102812124A (zh) * | 2009-08-26 | 2012-12-05 | 器官平衡有限责任公司 | 用于产生脂质的经遗传改造的生物 |
CN103336065A (zh) * | 2013-01-15 | 2013-10-02 | 东南大学 | 一种同时提取和检测生物介质中多种激素及其代谢物的方法 |
CN112964809A (zh) * | 2019-12-13 | 2021-06-15 | 中国科学院大连化学物理研究所 | 一种检测生物体液多种类固醇激素试剂盒及其使用方法 |
CN114813989A (zh) * | 2022-02-25 | 2022-07-29 | 东南大学 | 毛发中褪黑素、n-乙酰血清素、6-羟基褪黑素、皮质醇和可的松同时提取和检测方法 |
Non-Patent Citations (2)
Title |
---|
类固醇激素在环境中的污染现状及归趋;杨雷 等;《生态毒理学报》;第14卷(第5期);摘要,表1 * |
褪黑素与血压昼夜节律的相关性研究;黄丽红 等;《潍坊医学院学报》;第28卷(第6期);摘要,第405页第一段 * |
Also Published As
Publication number | Publication date |
---|---|
CN116699003A (zh) | 2023-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jiang et al. | Serum level of brain-derived neurotrophic factor in Parkinson's disease: a meta-analysis | |
Li et al. | Application of high-resolution metabolomics to identify biological pathways perturbed by traffic-related air pollution | |
Sun et al. | Identification of potential metabolic biomarkers of polycystic ovary syndrome in follicular fluid by SWATH mass spectrometry | |
Shirotsuki et al. | Salivary cortisol and DHEA reactivity to psychosocial stress in socially anxious males | |
Gao et al. | Determination of endocannabinoids and N-acylethanolamines in human hair with LC-MS/MS and their relation to symptoms of depression, burnout, and anxiety | |
WO2022206264A1 (zh) | 用于诊断和治疗脑白质病变的方法及其应用 | |
Gu et al. | Vitamin D status and its association with season, depression in stroke | |
Liang et al. | Untargeted Metabolomic Profiling Using UHPLC‐QTOF/MS Reveals Metabolic Alterations Associated with Autism | |
Tang et al. | Quality markers of animal medicinal materials: correlative analysis of musk reveals distinct metabolic changes induced by multiple factors | |
MacDonald et al. | Laser capture microdissection–targeted mass spectrometry: a method for multiplexed protein quantification within individual layers of the cerebral cortex | |
Dong et al. | A UHPLC-MS/MS method for profiling multifunctional steroids in human hair | |
Xu et al. | Comparison of the metabolic profiles in the plasma and urine samples between autistic and typically developing boys: a preliminary study | |
Ghirotto et al. | MS‐Driven Metabolic Alterations Are Recapitulated in iPSC‐Derived Astrocytes | |
CN116699003B (zh) | 昼夜节律体液标志物组合及其uplc-ms/ms检测方法 | |
Janzen et al. | UPLC–MS/MS analysis of C5-acylcarnitines in dried blood spots | |
US10996205B2 (en) | Stress biomarkers and related non-invasive detection methods | |
Liu et al. | Differential expression of aerobic oxidative metabolism-related proteins in diabetic urinary exosomes | |
Cristoni et al. | Analysis of 21‐deoxycortisol, a marker of congenital adrenal hyperplasia, in blood by atmospheric pressure chemical ionization and electrospray ionization using multiple reaction monitoring | |
Mercimek-Mahmutoglu et al. | Screening for X-linked creatine transporter (SLC6A8) deficiency via simultaneous determination of urinary creatine to creatinine ratio by tandem mass-spectrometry | |
Xu et al. | UPLC-MS/MS simultaneous quantification of urinary circadian rhythm hormones and related metabolites: application to air traffic controllers | |
Chen et al. | Fatigue detection of air traffic controllers using metabolomic methods | |
WO2008125805A1 (en) | Metabolic profiling of fatty acid amides and its use in the diagnosis of and screening of drugs for schizophrenia | |
Kang et al. | Determination of the stress biomarker corticosterone in serum of tumor‐bearing mice by surrogate‐based liquid chromatography–tandem mass spectrometry | |
Wang et al. | Identification of adolescent patients with depression via assessment of the niacin skin flushing response | |
Wolkowitz et al. | Specificity of plasma HVA response to dexamethasone in psychotic depression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Li Qingyan Inventor after: Liu Yongsuo Inventor after: Li Boye Inventor after: Xu Weizhe Inventor after: Cui Yujing Inventor after: Guo Danming Inventor after: Wang Wei Inventor after: Xu Haishan Inventor after: Qiao Shi Inventor after: Yu Hongyan Inventor after: Ji Enhui Inventor before: Li Qingyan Inventor before: Liu Yongsuo Inventor before: Li Boye Inventor before: Xu Weizhe Inventor before: Cui Yujing Inventor before: Guo Danming Inventor before: Wang Wei Inventor before: Xu Haishan Inventor before: Qiao Shi Inventor before: Yu Hongyan Inventor before: Ji Enhui |
|
GR01 | Patent grant | ||
GR01 | Patent grant |